



## **Curetis To Attend Key Conferences in the First Half of 2020**

**Amsterdam, the Netherlands, and Holzgerlingen, Germany, January 23, 2020, 10:00 am CET** - Curetis N.V. (the "**Company**" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that the Curetis Group Companies will be attending several key conferences in the first half of 2020.

### February 2020

**First Coast Infectious Disease/Clinical Microbiology Symposium 27th Annual Meeting**  
January 31 – February 1, 2020 – Ponte Vedra Beach, FL (Curetis USA Inc.)

### March 2020

#### **4th AMR Conference 2020**

March 12-13, 2020 – Congress Center, Basel, Switzerland (Ares Genetics)

#### **South Central Association for Clinical Microbiology (SCACM) 50th Anniversary Spring Meeting/Symposium**

March 18-21, 2020 – Louisville, KY (Curetis USA Inc.)

### April 2020

#### **Northeast Association of Clinical Microbiology and Infectious Disease (NACMID)**

April 6-7, 2020 – Portsmouth, NH (Curetis USA Inc.)

#### **30th ECCMID European Society of Clinical Microbiology and infectious Diseases**

April 18-21, 2020 – Paris, France (Curetis GmbH), Booth #141A

### May 2020

#### **ASM Clinical Virology Symposium (CVS), Booth #425**

May 3-5, 2020 – West Palm Beach, FL (Curetis USA Inc.)

#### **23rd Annual Making A Difference in Infectious Diseases Meeting (MAD-ID)**

May 27-30, 2020 – Orlando, FL (Curetis USA Inc.)

### June 2020

#### **ASM Microbe 2020**

June 19-21, 2020 – Chicago, IL (Curetis USA Inc.), Booth #1303

###

## **About Curetis**

Curetis N.V.'s (Euronext: CURE) goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.

Curetis' Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures, thereby facilitating improved patient outcomes, stringent antibiotic stewardship and health-economic benefits. Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.

Curetis' wholly owned subsidiary Ares Genetics GmbH offers next-generation solutions for infectious disease diagnostics and therapeutics. The ARES Technology Platform combines what the Company believes to be the most comprehensive database worldwide on the genetics of antimicrobial resistances, *ARESdb*, with advanced bioinformatics and artificial intelligence.

**For further information, please visit [www.curetis.com](http://www.curetis.com) and [www.ares-genetics.com](http://www.ares-genetics.com).**

## **Legal Disclaimer**

This document constitutes neither an offer to buy nor an offer to subscribe for securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.

The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.

This press release includes statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "targets," "may," "will," or "should" and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis' actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

## **Contact details**

### **Curetis' Contact Details**

Curetis N.V.  
Max-Eyth-Str. 42

71088 Holzgerlingen, Germany  
Tel. +49 7031 49195-10  
[pr@curetis.com](mailto:pr@curetis.com) or [ir@curetis.com](mailto:ir@curetis.com)  
[www.curetis.com](http://www.curetis.com) - [www.unyvero.com](http://www.unyvero.com)

**International Media & Investor Inquiries**

akampion

Dr. Ludger Wess / Ines-Regina Buth

Managing Partners

[info@akampion.com](mailto:info@akampion.com)

Tel. +49 40 88 16 59 64

Tel. +49 30 23 63 27 68